A Novel Catheter Enterogenesis Device to Treat Short Bowel Syndrome

Information

  • Research Project
  • 8296352
  • ApplicationId
    8296352
  • Core Project Number
    R44DK085765
  • Full Project Number
    5R44DK085765-03
  • Serial Number
    085765
  • FOA Number
    PA-10-050
  • Sub Project Id
  • Project Start Date
    12/1/2009 - 14 years ago
  • Project End Date
    6/30/2014 - 10 years ago
  • Program Officer Name
    DENSMORE, CHRISTINE L
  • Budget Start Date
    7/1/2012 - 12 years ago
  • Budget End Date
    6/30/2014 - 10 years ago
  • Fiscal Year
    2012
  • Support Year
    03
  • Suffix
  • Award Notice Date
    6/28/2012 - 12 years ago
Organizations

A Novel Catheter Enterogenesis Device to Treat Short Bowel Syndrome

DESCRIPTION (provided by applicant): Short bowel syndrome (SBS) represents a large loss of intestinal length, compromising the absorption of nutrients and fluids to sustain life. Although patients may be maintained on parenteral (intravenous) nutrition, the morbidity can be devastating and associated mortality rates exceed 30%. Care for each SBS patient is in excess of $250,000 per year and estimated costs for just the first five years of the care of a child with SBS exceed 1.5 million. Although a number of strategies have been used to treat SBS, the results have been disappointing with high complication rates and death. Application of longitudinal distractive forces, as directed with an intraluminally placed device, induces intestinal growth in pig small intestine (1.7-fold) over a 7-day period. The lengthening (enterogenesis) is not merely a stretching of the intestine, but true growth with preservation of intestinal function. The goal of this proposal is to develop a catheter-based device which could be placed intralumenally for days to weeks in a clinical setting to deliver longitudinal forces to the intestine, allowing for an elongation of the bowel while keeping the continuity of the gastrointestinal tract intact. The catheter enterogenesis device (CED) is envisioned as a simple, effective means of improving survival for SBS sufferers. Phase 1 resulted in the successful development of a working prototype. Two inflated balloons effectively anchored to the intestinal wall and delivered the forces previously determined to be effective for enterogenesis. The aims of this proposal is to develop the insertion and removal technique for the device with a preference for endoscopic placement, to assess the safety of the device through blood flow measurements, gross tissue examination and histological assessment and finally to demonstrate the efficacy of the device to lengthen the bowel in a chronic study. Device development will accompany each stage. The overall impact of this device will provide a low cost, safe and effective device to treat patients with short bowel syndrome in response to a tremendous unmet need for patients and their families. Variations of the CED may treat disease processes in other hollow visceral organs such as esophageal and intestinal atresia, ischemic and infection processes resulting in massive colon resection and congenital exstrophy.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R44
  • Administering IC
    DK
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    455717
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
    NIDDK:455717\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MC3, INC.
  • Organization Department
  • Organization DUNS
    806687406
  • Organization City
    DEXTER
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    481301563
  • Organization District
    UNITED STATES